CL2017003436A1 - Compuestos de benzoxacepina oxazolidinona y métodos de uso - Google Patents
Compuestos de benzoxacepina oxazolidinona y métodos de usoInfo
- Publication number
- CL2017003436A1 CL2017003436A1 CL2017003436A CL2017003436A CL2017003436A1 CL 2017003436 A1 CL2017003436 A1 CL 2017003436A1 CL 2017003436 A CL2017003436 A CL 2017003436A CL 2017003436 A CL2017003436 A CL 2017003436A CL 2017003436 A1 CL2017003436 A1 CL 2017003436A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- pi3k
- benzoxacepin
- oxazolidinone compounds
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B43/00—Formation or introduction of functional groups containing nitrogen
- C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>EN EL PRESENTE DOCUMENTO SE DESCRIBEN COMPUESTOS DE BENZOXACEOINA OXAZOLIDINONA CON ACTIVIDAD O FUNCIÓN MODULADORA DE FOSFOINOSITIDO 3 CINASA (PI3K) QUE TIENEN LA ESTRUCTURA DE FÓRMULA 1, O ESTEREOISÓMEROS, TAUTÓMEROS, O SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, Y CON LOS SUSTITUYENTES Y CARACTERÍSTICAS ESTRUCTURALES DESCRITAS EN EL PRESENTE DOCUMENTO. TAMBIÉN SE DESCRIBEN COMPOSICIONES FARMACÉUTICAS Y MEDICAMENTOS QUE INCLUYEN LOS COMPUESTOS DE FÓRMULA 1, ASÍ COMO MÉTODOS PARA USAR DICHOS MODULADORES DE PI3K, SOLOS O EN COMBINACIÓN CON OTROS AGENTES TERAPÉUTICOS, PARA TRATAR ENFERMEDADES O AFECCIONES QUE ESTÁN MEDIADAS O QUE SON DEPENDIENTES DE LA DESREGULACIÓN DE PI3K.</p>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562188029P | 2015-07-02 | 2015-07-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2017003436A1 true CL2017003436A1 (es) | 2018-05-04 |
Family
ID=56292756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2017003436A CL2017003436A1 (es) | 2015-07-02 | 2017-12-28 | Compuestos de benzoxacepina oxazolidinona y métodos de uso |
Country Status (34)
Country | Link |
---|---|
US (6) | US9650393B2 (es) |
EP (4) | EP3567045B1 (es) |
JP (4) | JP6523490B2 (es) |
KR (2) | KR102014326B1 (es) |
CN (4) | CN112047960B (es) |
AR (1) | AR105238A1 (es) |
AU (2) | AU2016287463B2 (es) |
CA (1) | CA2982708C (es) |
CL (1) | CL2017003436A1 (es) |
CO (1) | CO2017011038A2 (es) |
CR (1) | CR20170563A (es) |
DK (1) | DK3317284T3 (es) |
ES (2) | ES2764497T3 (es) |
HK (1) | HK1253003A1 (es) |
HR (1) | HRP20192349T1 (es) |
HU (1) | HUE046756T2 (es) |
IL (3) | IL255200B (es) |
LT (1) | LT3317284T (es) |
MA (3) | MA49861A (es) |
MX (2) | MX2020003415A (es) |
MY (1) | MY195002A (es) |
NZ (2) | NZ736222A (es) |
PE (2) | PE20181021A1 (es) |
PH (2) | PH12017502425A1 (es) |
PL (2) | PL3567045T3 (es) |
PT (1) | PT3317284T (es) |
RS (1) | RS59740B1 (es) |
RU (1) | RU2730529C2 (es) |
SG (1) | SG10201913980SA (es) |
SI (1) | SI3317284T1 (es) |
TW (4) | TWI698440B (es) |
UA (1) | UA121678C2 (es) |
WO (1) | WO2017001645A1 (es) |
ZA (1) | ZA201808370B (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3094197C (en) | 2015-07-02 | 2023-02-28 | F. Hoffmann-La Roche Ag | Bicyclic lactams and methods of use thereof |
WO2017001658A1 (en) | 2015-07-02 | 2017-01-05 | F. Hoffmann-La Roche Ag | Benzoxazepin oxazolidinone compounds and methods of use |
UA121678C2 (uk) * | 2015-07-02 | 2020-07-10 | Ф. Хоффманн-Ля Рош Аг | Сполука бензоксазепіноксазолідинонів та способи застосування |
JP6873977B2 (ja) | 2015-09-08 | 2021-05-19 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 三環式pi3k阻害化合物及び使用方法 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
WO2018073193A1 (en) | 2016-10-17 | 2018-04-26 | F. Hoffmann-La Roche Ag | Bicyclic pyridone lactams and methods of use thereof |
EP3851441B1 (en) * | 2016-12-15 | 2023-06-28 | F. Hoffmann-La Roche AG | Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide |
US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
WO2018197653A1 (en) * | 2017-04-28 | 2018-11-01 | F. Hoffmann-La Roche Ag | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production |
JP7398391B2 (ja) | 2018-04-20 | 2023-12-14 | エフ. ホフマン-ラ ロシュ アーゲー | N-[4-オキソ-2,3-ジヒドロ-1,5-ベンズオキサゼピン-3-イル]-5,6-ジヒドロ-4H-ピロロ[1,2-b]ピラゾール-2-カルボキサミド誘導体及び例えば過敏性腸症候群(IBS)を処置するためのRIP1キナーゼ阻害剤としての関連化合物 |
JP7456945B2 (ja) * | 2018-05-30 | 2024-03-27 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | 三環式誘導体を含む阻害剤、その製造方法、及び使用 |
WO2020023297A1 (en) * | 2018-07-23 | 2020-01-30 | Genentech, Inc. | Methods of treating cancer with pi3k inhibitor, gdc-0077 |
TW202027736A (zh) | 2018-10-08 | 2020-08-01 | 瑞士商赫孚孟拉羅股份公司 | 用PI3Kα抑制劑及二甲雙胍治療癌症之方法 |
CN109265408B (zh) * | 2018-12-11 | 2020-09-01 | 上海皓元生物医药科技有限公司 | 二氟甲基取代噁烷-2-酮的合成方法 |
CN113195000A (zh) | 2018-12-21 | 2021-07-30 | 第一三共株式会社 | 抗体-药物缀合物和激酶抑制剂的组合 |
CN111995541A (zh) * | 2019-05-27 | 2020-11-27 | 润佳(苏州)医药科技有限公司 | 含有稳定重同位素的酰胺官能团的化合物及其应用 |
CN114599656A (zh) * | 2019-11-04 | 2022-06-07 | 贝达药业股份有限公司 | 咪唑烷酮类化合物及其制备方法与应用 |
CN112830935B (zh) * | 2019-11-25 | 2023-12-22 | 上海翰森生物医药科技有限公司 | 含三并环类衍生物自由碱的晶型及其药物组合物 |
AU2020389670A1 (en) * | 2019-11-25 | 2022-05-19 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof |
IL293347A (en) * | 2019-12-03 | 2022-07-01 | Genentech Inc | Combined therapies for the treatment of breast cancer |
EP4259662A1 (en) | 2020-12-11 | 2023-10-18 | Genentech, Inc. | Combination therapies for treatment of her2 cancer |
JP2024504811A (ja) * | 2021-01-29 | 2024-02-01 | メッドシャイン ディスカバリー インコーポレイテッド | 三環式化合物及びその使用 |
MX2023013305A (es) | 2021-05-13 | 2024-01-31 | Betta Pharmaceuticals Co Ltd | Compuesto polimorfo de imidazolidinona, método de preparación del mismo y uso del mismo. |
IL308457A (en) | 2021-05-28 | 2024-01-01 | Genentech Inc | A process for preparing benzoxazepine oxazolidinone compounds |
EP4358550A4 (en) | 2021-07-19 | 2024-10-16 | Kyocera Corp | COMMUNICATION PROCESS |
US20230321102A1 (en) | 2022-04-06 | 2023-10-12 | Genentech, Inc. | TREATMENT OF CANCER USING COMBINATION THERAPIES COMPRISING GDC-6036 and GDC-0077 |
WO2024022435A1 (zh) * | 2022-07-27 | 2024-02-01 | 南京明德新药研发有限公司 | 一种5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英化合物的晶型及其制备方法 |
WO2024100236A1 (en) | 2022-11-11 | 2024-05-16 | Astrazeneca Ab | Combination therapies for the treatment of cancer |
WO2024206147A1 (en) | 2023-03-24 | 2024-10-03 | Arvinas Operations, Inc. | Dosage regimens of estrogen receptor degraders |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US5846824A (en) | 1994-02-07 | 1998-12-08 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
US6274327B1 (en) | 1992-04-13 | 2001-08-14 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
GB9208135D0 (en) | 1992-04-13 | 1992-05-27 | Ludwig Inst Cancer Res | Polypeptides having kinase activity,their preparation and use |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
ES2527754T3 (es) | 2000-04-25 | 2015-01-29 | Icos Corporation | Inhibidores de la isoforma delta de la fosfatidilinositol 3-quinasa humana |
EP2088147A1 (en) | 2003-12-22 | 2009-08-12 | Arcadia Pharmaceuticals Inc. | Dibenzo-condensed azepine, diazepine, oxazepine and thiazepine derivatives as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
PT3153514T (pt) | 2004-05-13 | 2021-06-25 | Icos Corp | Quinazolinonas como inibidoras da fosfatidilinositol 3-quinase delta humana |
GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
WO2006117670A1 (en) | 2005-05-04 | 2006-11-09 | Pfizer Limited | 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c |
RS51782B (en) | 2005-10-07 | 2011-12-31 | Exelixis Inc. | AZETIDINS AS MAK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
ES2347187T3 (es) | 2006-04-26 | 2010-10-26 | F. Hoffmann-La Roche Ag | Derivado de tieno(3,2-d)pirimidina, util como un inhibidor de pi3k. |
GB0610866D0 (en) | 2006-06-02 | 2006-07-12 | Hammersmith Imanet Ltd | Novel in vivo imaging compounds |
PT2526933E (pt) | 2006-09-22 | 2015-06-23 | Pharmacyclics Inc | Inibidores da tirosina-quinase de bruton |
AR064106A1 (es) * | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
BRPI0717923A2 (pt) * | 2006-12-07 | 2013-10-22 | Genentech In | '' composto, composição farmacêutica, método para tratar um câncer, processo para a produção de uma composição farmacêutica, usos, métodos para inibir ou modular a atividade da lipídeo quinase e kit ' ' |
CN101918380B (zh) * | 2007-11-21 | 2014-09-24 | 解码遗传Ehf公司 | 用于治疗炎性、心血管和cns病症的取代苯并唑pde4抑制剂 |
UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
CA2772691C (en) * | 2009-09-28 | 2017-10-03 | F. Hoffmann-La Roche Ag | Benzoxazepin pi3k inhibitor compounds and methods of use |
CN104987345A (zh) | 2009-09-28 | 2015-10-21 | 霍夫曼-拉罗奇有限公司 | 苯并氧杂*pi3k抑制剂化合物和使用方法 |
US20120231015A1 (en) * | 2009-11-06 | 2012-09-13 | Emory University | Fragile x mental retardation protein (fmrp), compositions, and methods related thereto |
KR20140032383A (ko) | 2011-03-21 | 2014-03-14 | 에프. 호프만-라 로슈 아게 | Pi3k p110 델타에 대하여 선택적인 벤즈옥사제핀 화합물 및 이의 사용 방법 |
NO3175985T3 (es) | 2011-07-01 | 2018-04-28 | ||
JP5832647B2 (ja) | 2011-07-01 | 2015-12-16 | ノバルティス アーゲー | がんの治療における使用のためのcdk4/6阻害剤およびpi3k阻害剤を含む併用療法 |
UY34632A (es) * | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
MD20140100A2 (ro) | 2012-03-05 | 2015-01-31 | Gilead Calistoga Llc | Forme polimorfe ale (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilchinazolin-4(3H)-onei |
WO2013149184A1 (en) * | 2012-03-30 | 2013-10-03 | Brigham Young University | Effort modulation for process control of friction stir operations |
KR101689946B1 (ko) | 2012-06-08 | 2016-12-26 | 에프. 호프만-라 로슈 아게 | 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물 |
US9303043B2 (en) | 2013-03-13 | 2016-04-05 | Greentech, Inc. | Process for making benzoxazepin compounds |
JP6260967B2 (ja) * | 2013-11-06 | 2018-01-17 | 国立大学法人京都大学 | 放射性ヨウ素標識化合物、及び、これを含む放射性医薬 |
WO2017001658A1 (en) | 2015-07-02 | 2017-01-05 | F. Hoffmann-La Roche Ag | Benzoxazepin oxazolidinone compounds and methods of use |
UA121678C2 (uk) | 2015-07-02 | 2020-07-10 | Ф. Хоффманн-Ля Рош Аг | Сполука бензоксазепіноксазолідинонів та способи застосування |
EP3851441B1 (en) | 2016-12-15 | 2023-06-28 | F. Hoffmann-La Roche AG | Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide |
WO2018197653A1 (en) * | 2017-04-28 | 2018-11-01 | F. Hoffmann-La Roche Ag | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production |
WO2020023297A1 (en) | 2018-07-23 | 2020-01-30 | Genentech, Inc. | Methods of treating cancer with pi3k inhibitor, gdc-0077 |
TW202027736A (zh) | 2018-10-08 | 2020-08-01 | 瑞士商赫孚孟拉羅股份公司 | 用PI3Kα抑制劑及二甲雙胍治療癌症之方法 |
IL293347A (en) | 2019-12-03 | 2022-07-01 | Genentech Inc | Combined therapies for the treatment of breast cancer |
-
2016
- 2016-07-01 UA UAA201800851A patent/UA121678C2/uk unknown
- 2016-07-01 AU AU2016287463A patent/AU2016287463B2/en active Active
- 2016-07-01 MX MX2020003415A patent/MX2020003415A/es unknown
- 2016-07-01 US US15/200,301 patent/US9650393B2/en active Active
- 2016-07-01 NZ NZ736222A patent/NZ736222A/en unknown
- 2016-07-01 DK DK16733600.7T patent/DK3317284T3/da active
- 2016-07-01 MA MA049861A patent/MA49861A/fr unknown
- 2016-07-01 KR KR1020177037599A patent/KR102014326B1/ko active IP Right Grant
- 2016-07-01 JP JP2017567428A patent/JP6523490B2/ja active Active
- 2016-07-01 MA MA054252A patent/MA54252A/fr unknown
- 2016-07-01 CN CN202010786032.4A patent/CN112047960B/zh active Active
- 2016-07-01 RU RU2018103454A patent/RU2730529C2/ru active
- 2016-07-01 TW TW108100214A patent/TWI698440B/zh active
- 2016-07-01 TW TW106122915A patent/TWI649326B/zh active
- 2016-07-01 RS RS20191662A patent/RS59740B1/sr unknown
- 2016-07-01 CA CA2982708A patent/CA2982708C/en active Active
- 2016-07-01 ES ES16733600T patent/ES2764497T3/es active Active
- 2016-07-01 PL PL19171677T patent/PL3567045T3/pl unknown
- 2016-07-01 CN CN202010779436.0A patent/CN112062778B/zh active Active
- 2016-07-01 NZ NZ775526A patent/NZ775526A/en unknown
- 2016-07-01 MY MYPI2017705097A patent/MY195002A/en unknown
- 2016-07-01 PT PT167336007T patent/PT3317284T/pt unknown
- 2016-07-01 SG SG10201913980SA patent/SG10201913980SA/en unknown
- 2016-07-01 LT LTEP16733600.7T patent/LT3317284T/lt unknown
- 2016-07-01 PE PE2017002721A patent/PE20181021A1/es unknown
- 2016-07-01 AR ARP160102006A patent/AR105238A1/es active IP Right Grant
- 2016-07-01 PL PL16733600T patent/PL3317284T3/pl unknown
- 2016-07-01 EP EP19171677.8A patent/EP3567045B1/en active Active
- 2016-07-01 MA MA42295A patent/MA42295B1/fr unknown
- 2016-07-01 ES ES19171677T patent/ES2908300T3/es active Active
- 2016-07-01 WO PCT/EP2016/065455 patent/WO2017001645A1/en active Application Filing
- 2016-07-01 CR CR20170563A patent/CR20170563A/es unknown
- 2016-07-01 HU HUE16733600A patent/HUE046756T2/hu unknown
- 2016-07-01 SI SI201630571T patent/SI3317284T1/sl unknown
- 2016-07-01 EP EP20174298.8A patent/EP3778607B1/en active Active
- 2016-07-01 TW TW105120987A patent/TWI601732B/zh active
- 2016-07-01 CN CN202010778340.2A patent/CN111909173A/zh active Pending
- 2016-07-01 CN CN201680039251.8A patent/CN107873032B/zh active Active
- 2016-07-01 EP EP22204250.9A patent/EP4212536A1/en active Pending
- 2016-07-01 EP EP16733600.7A patent/EP3317284B1/en active Active
- 2016-07-01 TW TW109117051A patent/TW202108592A/zh unknown
- 2016-07-01 KR KR1020197024122A patent/KR102306071B1/ko active IP Right Grant
- 2016-07-01 MX MX2017016344A patent/MX2017016344A/es active IP Right Grant
- 2016-07-01 PE PE2021000504A patent/PE20211775A1/es unknown
-
2017
- 2017-04-07 US US15/481,764 patent/US20170210733A1/en not_active Abandoned
- 2017-10-10 US US15/729,507 patent/US10112932B2/en active Active
- 2017-10-22 IL IL255200A patent/IL255200B/en active IP Right Grant
- 2017-10-27 CO CONC2017/0011038A patent/CO2017011038A2/es unknown
- 2017-12-22 PH PH12017502425A patent/PH12017502425A1/en unknown
- 2017-12-28 CL CL2017003436A patent/CL2017003436A1/es unknown
-
2018
- 2018-09-24 US US16/140,392 patent/US10851091B2/en active Active
- 2018-09-27 HK HK18112369.8A patent/HK1253003A1/zh unknown
- 2018-12-11 ZA ZA2018/08370A patent/ZA201808370B/en unknown
-
2019
- 2019-04-24 JP JP2019083107A patent/JP6880101B2/ja active Active
- 2019-12-30 HR HRP20192349TT patent/HRP20192349T1/hr unknown
-
2020
- 2020-01-27 IL IL272277A patent/IL272277B/en active IP Right Grant
- 2020-07-01 AU AU2020204418A patent/AU2020204418B2/en active Active
- 2020-08-24 PH PH12020551315A patent/PH12020551315A1/en unknown
- 2020-10-04 IL IL277774A patent/IL277774A/en unknown
- 2020-10-20 US US17/075,583 patent/US11760753B2/en active Active
-
2021
- 2021-04-12 JP JP2021067023A patent/JP7266630B2/ja active Active
-
2023
- 2023-04-18 JP JP2023067993A patent/JP2023103242A/ja active Pending
- 2023-08-04 US US18/365,392 patent/US20240199594A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017003436A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
CO2020000145A2 (es) | Carboxamidas como moduladores de los canales de sodio | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
UY37098A (es) | Moduladores de ror-gamma | |
CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
BR112018006259A2 (pt) | "adjunto compressível com estruturas de suporte intermediárias" | |
CL2019002810A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos. | |
EA201591403A1 (ru) | Спиролактамные модуляторы рецептора nmda и их применение | |
CR20160203A (es) | Inhibidores de tirosina cinasa de bruton | |
CR20170116A (es) | Compuestos que inhiben la proteina mcl-1 | |
CL2019001993A1 (es) | Inhibidores selectivos de jak1. | |
BR112016028288A2 (pt) | ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto? | |
CR20140365A (es) | Compuestos de carbamato y preparación y uso de los mismos | |
CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
CL2013003160A1 (es) | Compuestos derivados de 4h-cromen-4-ona moduladores de la proteina cinasa pi3k; compuestos intermediarios; composicion farmaceutica que los comprende; y utiles en el tratamiento del cancer, agentes antinflamatorios, inmunosupresores, esteroides, analgesicos, leucemia, entre otros. | |
BR112015011760A2 (pt) | composto, uso do composto, e uso de uma composição farmacêutica | |
ECSP20018487A (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
EA201591404A1 (ru) | Спиролактамные модуляторы рецептора nmda и их применение | |
DOP2016000226A (es) | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados | |
ECSP17074645A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
CR20160047A (es) | Inhibidores de rorc2 y sus métodos de uso |